Edition:
United States

People: Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.20EUR
11:37am EST
Change (% chg)

€0.65 (+0.88%)
Prev Close
€73.55
Open
€74.07
Day's High
€74.79
Day's Low
€74.01
Volume
2,290,081
Avg. Vol
2,077,294
52-wk High
€92.97
52-wk Low
€72.63

Brandicourt, Olivier 

Mr. Olivier Brandicourt has served as Chairman of the Executive Committee, Chief Executive Officer, Director of Sanofi S.A. since May 4, 2015. He was Chairman of the Executive Committee, Chief Executive Officer of the Company from April 2, 2015 to May 4, 2015. He is Member of the Strategy Committee of the Company. He has 28 years of global experience in the pharmaceutical industry. He joined the Company after serving as Chief Executive Officer of Bayer Healthcare AG since 2013. He worked at Pfizer for 13 years, where he most recently served as Member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units. Over his career at Pfizer, he served in a series of leadership positions, including heading its Global Primary Care business unit from 2009 to 2012 and its Global Specialty Care business unit from 2008 to 2009. He also led its Cardiology business in the United States, as well as several regional operations around the world. Brandicourt started his career as a Medical Director for the Region Africa at Warner-Lambert/Parke-Davis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada. He also spent eight years with the Institute of Infectious and Tropical Diseases at the Pitie-Salpetriere Hospital in Paris with a focus on malaria research in West and Central Africa and two years in the Republic of Congo as a doctor. He is also an Honorary Member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. He studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine (Universite Paris V Rene Descartes) and holds an Advanced Degree in Cellular and Immunological Pathophysiology from Universite Paris V Rene Descartes. He also holds a Master’s Degree in Biology (Universite Paris XII Val de Marne).

Basic Compensation

Total Annual Compensation, EUR 2,895,460
Restricted Stock Awards, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR 133
Fiscal Year Total, EUR 2,895,590

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --